Advertisement
Home »

Lecanemab May Slow Decline of Cognition and Function in AD

May 08, 2023

REFERENCES & ADDITIONAL READING

Source: Van Dyck CH. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer’s disease (CLARITY AD). PL5.005, AAN 2023 Annual Meeting, 22–27 April, Boston, USA.

ABOUT THE CONTRIBUTORS

Author

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement